Should you buy Lexicon Pharmaceuticals stock? (NasdaqGS:LXRX). Let's see how it does in our automated value investing analysis system.
(Lexicon Pharmaceuticals stock price per share)
||LXRX Fair Price
(based on intrinsic value)
|LXRX Safety Price (based on a variable margin of safety)||$45.78|
|PE Ratio versus Sector||34% lower than other Healthcare stocks|
|PE Ratio versus Industry||77% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||99%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 3,641,116 shares shorted. With 58,710,967 shares available for purchase and an average trading volume over the past 10 trading days of 956,562, it would take at least 3.806 days for all of the short holders to cover their shorts.
We believe that Lexicon Pharmaceuticals may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Even better, Lexicon Pharmaceuticals looks like a stock on sale. Based on our analysis—if the company keeps making money the way it has been—you may be looking at a bargain. Keep this stock in mind as you put together your portfolio! See Before You Buy for your next steps (and read our disclaimer about investing risk).
Does Lexicon Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles